Skip to main content
Erschienen in: Tumor Biology 12/2016

12.10.2016 | Original Article

Prognostic risk factors in patients with bone metastasis from colorectal cancer

verfasst von: Fangqi Liu, Jiang Zhao, Jie Xie, Li Xie, Ji Zhu, Sanjun Cai, Hongtu Zheng, Ye Xu

Erschienen in: Tumor Biology | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

The morbidity of bone metastasis (BM) from colorectal cancer (CRC) is increasing more than ever; however, insufficient research on BM from CRC leads to reduced awareness of the issue. Therefore, the aim of this study was to evaluate the clinical features and prognostic risk factors of CRC patients with BM. Clinical data were retrospectively analyzed for a total of 242 CRC patients with BM. Of the 242 CRC patients with BM, 52 (21.5 %) had bone metastasis alone (BMA) and 190 (78.5 %) had both bone and visceral metastasis (BM&VM). The median survival time (MST) after the diagnosis of BM in all 242 patients was 15.6 months (95 % confidence interval [CI] 12.74–18.46 months). The MST of the BMA group was significantly longer than that of the BM&VM group (29.1 vs. 12.8 months, p = 0.003). Using a Cox proportional hazard model, we identified a high carcinoembryonic antigen (CEA) level and BMA as independent prognostic factors for CRC patients with BM. For the BMA group, the independent prognostic factors were elevated alkaline phosphatase (ALP) and perineural invasion of the primary cancer, which were distinct from the factors for the entire group of BM patients. Furthermore, we found that the BMA patients with multiple sites of BM had similar prognosis to the BM&VM patients. These findings together provide us with a further understanding of BM from CRC and reveal that BMA may be a distinct subset of BM from CRC that has unique independent prognostic factors and a good prognosis.
Literatur
1.
Zurück zum Zitat Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2(8):563–72.CrossRefPubMed Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2(8):563–72.CrossRefPubMed
2.
Zurück zum Zitat Kanthan R, Loewy J, Kanthan SC. Skeletal metastases in colorectal carcinomas: a Saskatchewan profile. Dis Colon rectum. 1999;42(12):1592–7. Kanthan R, Loewy J, Kanthan SC. Skeletal metastases in colorectal carcinomas: a Saskatchewan profile. Dis Colon rectum. 1999;42(12):1592–7.
3.
Zurück zum Zitat Santini D, Tampellini M, Vincenzi B, Ibrahim T, Ortega C, Virzi V et al. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Annals of oncology: official journal of the European Society for Santini D, Tampellini M, Vincenzi B, Ibrahim T, Ortega C, Virzi V et al. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Annals of oncology: official journal of the European Society for
4.
Zurück zum Zitat Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer. 2005;5(2):108–13.CrossRefPubMed Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer. 2005;5(2):108–13.CrossRefPubMed
5.
Zurück zum Zitat Douillard J-Y, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(31):4697–705.CrossRef Douillard J-Y, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(31):4697–705.CrossRef
6.
Zurück zum Zitat Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Journal of clinical oncology: official journal of the. Proc Am Soc Clin Oncol. 2008;26(12):2013–9.CrossRef Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Journal of clinical oncology: official journal of the. Proc Am Soc Clin Oncol. 2008;26(12):2013–9.CrossRef
7.
Zurück zum Zitat Van Cutsem E, Köhne C-H, Hitre E, Zaluski J, Chang Chien C-R, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17.CrossRefPubMed Van Cutsem E, Köhne C-H, Hitre E, Zaluski J, Chang Chien C-R, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17.CrossRefPubMed
8.
Zurück zum Zitat Besbeas S, Stearns MW. Osseous metastases from carcinomas of the colon and rectum. Dis Colon rectum. 1978;21(4):266–8. Besbeas S, Stearns MW. Osseous metastases from carcinomas of the colon and rectum. Dis Colon rectum. 1978;21(4):266–8.
9.
Zurück zum Zitat Nozue M, Oshiro Y, Kurata M, Seino K-I, Koike N, Kawamoto T, et al. Treatment and prognosis in colorectal cancer patients with bone metastasis. Oncol Rep. 2002;9(1):109–12.PubMed Nozue M, Oshiro Y, Kurata M, Seino K-I, Koike N, Kawamoto T, et al. Treatment and prognosis in colorectal cancer patients with bone metastasis. Oncol Rep. 2002;9(1):109–12.PubMed
10.
Zurück zum Zitat Harries M, Taylor A, Holmberg L, Agbaje O, Garmo H, Kabilan S, et al. Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients. Cancer Epidemiol. 2014;38(4):427–34.CrossRefPubMed Harries M, Taylor A, Holmberg L, Agbaje O, Garmo H, Kabilan S, et al. Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients. Cancer Epidemiol. 2014;38(4):427–34.CrossRefPubMed
11.
Zurück zum Zitat Qiu M, Hu J, Yang D, Cosgrove DP, Xu R. Pattern of distant metastases in colorectal cancer: a SEER based study. Oncotarget. 2015;6(36):38658–66.PubMedPubMedCentral Qiu M, Hu J, Yang D, Cosgrove DP, Xu R. Pattern of distant metastases in colorectal cancer: a SEER based study. Oncotarget. 2015;6(36):38658–66.PubMedPubMedCentral
12.
Zurück zum Zitat Gutman M, Fidler IJ. Biology of human colon cancer metastasis. World J Surg. 1995;19(2):226–34.CrossRefPubMed Gutman M, Fidler IJ. Biology of human colon cancer metastasis. World J Surg. 1995;19(2):226–34.CrossRefPubMed
13.
Zurück zum Zitat Takagawa R, Fujii S, Ohta M, Nagano Y, Kunisaki C, Yamagishi S, et al. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol. 2008;15(12):3433–9.CrossRefPubMed Takagawa R, Fujii S, Ohta M, Nagano Y, Kunisaki C, Yamagishi S, et al. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol. 2008;15(12):3433–9.CrossRefPubMed
14.
Zurück zum Zitat Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon rectum. 1994;37(3):272–7. Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon rectum. 1994;37(3):272–7.
15.
Zurück zum Zitat Rama N, Monteiro A, Bernardo JE, Eugénio L, Antunes MJ. Lung metastases from colorectal cancer: surgical resection and prognostic factors. European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery. 2009;35(3):444–9.CrossRef Rama N, Monteiro A, Bernardo JE, Eugénio L, Antunes MJ. Lung metastases from colorectal cancer: surgical resection and prognostic factors. European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery. 2009;35(3):444–9.CrossRef
16.
Zurück zum Zitat Regnard JF, Grunenwald D, Spaggiari L, Girard P, Elias D, Ducreux M, et al. Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg. 1998;66(1):214–8 - discussion 8-9.CrossRefPubMed Regnard JF, Grunenwald D, Spaggiari L, Girard P, Elias D, Ducreux M, et al. Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg. 1998;66(1):214–8 - discussion 8-9.CrossRefPubMed
17.
Zurück zum Zitat Farley JR, Baylink DJ. Skeletal alkaline phosphatase activity as a bone formation index in vitro. Metab Clin Exp. 1986;35(6):563–71.CrossRefPubMed Farley JR, Baylink DJ. Skeletal alkaline phosphatase activity as a bone formation index in vitro. Metab Clin Exp. 1986;35(6):563–71.CrossRefPubMed
18.
Zurück zum Zitat Mountzios G, Ramfidis V, Terpos E, Syrigos KN. Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data. Clinical lung cancer. 2011;12(6):341–9.CrossRefPubMed Mountzios G, Ramfidis V, Terpos E, Syrigos KN. Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data. Clinical lung cancer. 2011;12(6):341–9.CrossRefPubMed
19.
Zurück zum Zitat Liebig C, Ayala G, Wilks JA, Berger DH, Albo D. Perineural invasion in cancer: a review of the literature. Cancer. 2009;115(15):3379–91.CrossRefPubMed Liebig C, Ayala G, Wilks JA, Berger DH, Albo D. Perineural invasion in cancer: a review of the literature. Cancer. 2009;115(15):3379–91.CrossRefPubMed
20.
Zurück zum Zitat Kim HR, Min BS, Kim JS, Shin SJ, Ahn JB, Rho JK, et al. Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis. Oncology. 2011;81(3–4):175–83.CrossRefPubMed Kim HR, Min BS, Kim JS, Shin SJ, Ahn JB, Rho JK, et al. Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis. Oncology. 2011;81(3–4):175–83.CrossRefPubMed
21.
Zurück zum Zitat Delva R, Pein F, Lortholary A, Gamelin E, Cellier P, Larra F. [bone metastases of colorectal cancers: apropos of 8 cases]. La Revue de Médecine Interne. 1993;14(4):223–8.CrossRefPubMed Delva R, Pein F, Lortholary A, Gamelin E, Cellier P, Larra F. [bone metastases of colorectal cancers: apropos of 8 cases]. La Revue de Médecine Interne. 1993;14(4):223–8.CrossRefPubMed
Metadaten
Titel
Prognostic risk factors in patients with bone metastasis from colorectal cancer
verfasst von
Fangqi Liu
Jiang Zhao
Jie Xie
Li Xie
Ji Zhu
Sanjun Cai
Hongtu Zheng
Ye Xu
Publikationsdatum
12.10.2016
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 12/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5465-4

Weitere Artikel der Ausgabe 12/2016

Tumor Biology 12/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.